Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Vibrating platform may reduce fall risk for cancer survivors

NCT ID NCT07508527

Symptom relief Sponsor: Cairo University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether standing on a vibrating platform (whole body vibration) for 15 minutes, three times a week for eight weeks, can improve balance, reduce fear of falling, and enhance quality of life in people with nerve damage from chemotherapy. Thirty adults aged 30-60 with mild to moderate neuropathy will be randomly assigned to either standard physical therapy alone or standard therapy plus whole body vibration. The goal is to see if the vibration therapy adds extra benefit for postural control and fall prevention.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Whole body vibration therapy (a device-based intervention)
What this could lead to
If it works, this could offer a simple, drug-free way to improve balance and reduce fall risk for people with nerve damage from chemotherapy.
What could go wrong
This is a small, early-stage trial with only 30 participants, so results may not apply to everyone. The therapy is added to standard exercise, so any benefit may be modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 30 patients diagnosed with chemotherapy-induced peripheral neuropathy from both genders. * Their ages will range from 30-60 years old. * All patients included in this study will be on chemotherapy from at least one cycle as a treatment of malignant tumor. * The patients will be mild to moderate neuropathy according to mTNS. * They were medically stable. Exclusion Criteria: * History of other types of neuropathies (i.e., hereditry peripheral neuropathy associated with nutritional agents and paraneoplastic syndrome-related neuropathy…etc). * Unstable medical condition during chemotherapy * Patients who are starting new therapy or dose modification during study period * Morbid obesity body mass index \>40% * History of non-surgically repaired nerve compression injuries such as carpal tunnel, brachial plexopathy, spinal stenosis, and spinal nerve root compression * History of central nervous system primary or metastatic malignancy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Balance are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chemotherapy-induced neuropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Balance Chemotherapy induced peripheral neuropathy (CIPN) Fall risk, fall prevention Quality of life Whole-body vibration

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.